Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects with Previously Untreated Extensive-stage Small-cell Lung Cancer

Diseases and Conditions Researched


What is the purpose of this trial?

The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for subjects with Extensive-Stage Small-Cell Lung Cancer (ES SCLC).

Participation Guidelines

Age: Any

Click here for detailed participation information for this trial.

Sponsor: Onyx Pharmaceuticals
Last Updated:
Study HIC#: 1311013003